20 articles
Breakthrough study reveals sepiapterin dramatically outperforms existing PKU therapy, offering hope for better metabolic control.
A 2025 mini-review synthesizes RCTs and meta-analyses showing hypertonic dextrose prolotherapy rivals or beats standard OA injections.
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
Researchers explore targeted immune strategies to improve pancreatic islet transplant success rates for diabetes treatment.
Researchers shift from systemic B-cell targeting to localized immune control, potentially improving transplant success rates.
New research reveals pulsed electromagnetic field therapy selectively enhances ATP-linked mitochondrial respiration, pointing to a specific cellular energy mechanism.
Weekly tirzepatide injections led to up to 22% weight loss in Japanese participants, with 96-100% achieving clinically significant results.
A dual-action therapy combining a glucose-responsive hydrogel with stem cell exosomes dramatically speeds diabetic wound closure in mice.
A landmark 9,000-patient trial finds balanced crystalloids and normal saline perform equally for children in septic shock.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
New research reveals how blood vessel maturity around transplanted insulin-producing cells determines long-term survival.
A newly identified protein shields the liver from alcohol injury by bridging mitochondria and fat droplets to enhance fatty acid oxidation.
A systematic review of 38 trials finds tirzepatide cuts HbA1c nearly 3x more than lixisenatide with similar GI side effect rates.
A new ESRRA-ATG5 axis links mitochondrial recycling to arginine metabolism, and a plant polyphenol activates it to protect diabetic kidneys.
Comprehensive therapy combining Western medicine, traditional Chinese medicine, and lifestyle changes reversed diabetes in majority of patients.
The TRIUMPH program tests retatrutide across 5,800+ patients using a novel basket trial design to simultaneously tackle obesity and its complications.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
The triple agonist retatrutide drives deep metabolic shifts beyond weight loss, improving key biomarkers of cardiovascular and insulin health.
A large real-world study finds post-transplant diabetes requiring insulin marks a high-risk metabolic phenotype with far worse graft and patient outcomes.
Brief weekly PEMF exposures increased quail embryo weight by ~20%, body length by ~15%, and upregulated key oxidative muscle genes.
